ARS Pharma develops and sells neffy, a nasal spray form of epinephrine for emergency treatment of severe allergic reactions. SPRY reports earnings on Thu, Nov 5, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Jun 25 | Leerink Partners | Maintained | Buy | |
| May 28 | Cantor Fitzgerald | Maintained | Buy |
Seasonality
How SPRY has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in SPRY in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SPRY is in one of them and how their past SPRY trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered SPRY in an article yet. Here's the latest on the wider market.
About ARS Pharmaceuticals
ARS Pharma is a biopharmaceutical company that develops and sells neffy, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis. The product is given through the nose without a needle, and it is sold under other trade names in Europe, the U.K. and China. Its customers include patients, caregivers, and the doctors who prescribe it, and partners help commercialize the product in several countries. The company is headquartered in San Diego, California.
- Headquarters
- San Diego, CA
- Founded
- 2016
- Website
- silverbacktx.com ↗